Yifat Reuveni

Ending ‘one size fits all’ trauma treatment

Why trauma research must look at women’s physiology and psyche – not just men's

For decades, medicine and medical research have rested on a quiet and dangerous assumption: that the male body is the universal standard. Drug development, resuscitation protocols and clinical trials were designed, tested and calibrated on men. The “one size fits all” approach dominated, leaving women as a statistical derivative of the male model. The price of this gender blindness is dramatic. Medical protocols that ignore women tend to be less effective, and at times even harmful. Data show that women are less likely than men to receive successful resuscitation and to survive an out-of-hospital cardiac arrest. Even in mental health, the use of hormonal contraceptives may, for example, reduce the effectiveness of exposure therapy for trauma.

The same phenomenon of deficient medicine now marks one of the most urgent fields in Israel: the study of trauma and post-trauma. To develop effective treatment protocols for the unprecedented psychological crisis that has struck us since October 7, the scientific and clinical community must ask itself a simple question: why do we keep measuring and assessing women’s trauma with male tools?

The first and most immediate reason to focus on women is their unique physiology. Trauma does not occur in a psychological vacuum; it is etched into the body. Recent studies, including research on psychedelic therapies for trauma, indicate that biological and hormonal factors are critical to treatment success. Sex hormones affect how drugs are broken down in the body, as well as the intensity of the emotional and therapeutic response. Different phases of the menstrual cycle, menopause, use of birth control pills and hormonal transitions all directly affect drug metabolism and the intensity of the therapeutic experience. To deliver evidence-based care, researchers and clinicians must start asking questions and actively collecting data on cycle phases, hormone use and sexual trauma. Ignoring female physiology is not merely scientific inaccuracy; it is clinical negligence.

The second reason concerns the architecture of survival and coping, which is entirely gender dependent. A comprehensive study by NATAL’s research department examining the consequences of the war revealed a clinical phenomenon that has been named “the Female Paradox.” The data show a vast gap between women’s functioning exterior and their inner collapse. While overall functioning levels of women and men in treatment were nearly identical, 55 percent of women reported a significant deterioration in their mental state (compared with 31% of men). Moreover, women reported significantly higher levels of anxiety and depression that crossed the clinical threshold, and 62% of women reported worsening of sleep difficulties, compared with 38% of men.

In other words, the traditional male model for diagnosing trauma usually looks for a “breakdown,” or for impaired outward functioning at work or in daily settings. But in women, the absence of functional impairment does not indicate resilience or the absence of trauma. Women display a phenomenal capacity for survival, maintaining a routine for those around them, probably because of their maternal role. But the body pays the somatic price, and distress builds up quietly, under the radar. If we continue to assess women, or to judge recovery, through the lens of return to functioning as the measure of healing, we may miss them, and they will fall through the cracks of the mental health system.

The challenges before us demand a research awakening. We need focused, rigorous research that examines how women process trauma, at both the physiological and the functional level, and how social roles (such as the burden of childcare or secondary exposure to trauma) shape the pathology. At the same time, researchers and clinicians must receive gender-sensitive training so they can recognize these needs.

Recognizing the impressive strength and heroism women have shown since the outbreak of the war is essential, but it can in no way serve as an excuse to ignore the heavy price women are paying. It is time to bury the “one size fits all” approach and move toward personalized, gender-sensitive, evidence-based care: care that sees the whole woman, biologically, psychologically and socially.

About the Author
Dr. Yifat Reuveni is the Director of the Research and Innovation Department at NATAL – Israel Trauma and Resiliency Center, where she leads strategic research initiatives and advances trauma-tech innovation development. Dr. Reuveni holds a Ph.D. in New Economics from McGill University, Canada. Previously, she directed the Arison ESG Center at Reichman University and was a member of an international research group at Oxford specializing in Social & Sustainable Finance. She has extensive experience in academic teaching, international research collaborations, and managing European Union-funded projects focused on social innovation and regional economic development.
Sign in or Register
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.